104 related articles for article (PubMed ID: 37871555)
1. HIV-1-specific T-cell responses and exhaustion profiles in people with HIV after switching to dual therapy vs. maintaining triple therapy based on integrase inhibitors.
Muñoz-Muela E; Trujillo-Rodríguez M; Serna-Gallego A; Saborido-Alconchel A; Ruiz-Mateos E; López-Cortés LF; Gutiérrez-Valencia A
Biomed Pharmacother; 2023 Dec; 168():115750. PubMed ID: 37871555
[TBL] [Abstract][Full Text] [Related]
2. Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trial.
Trujillo-Rodríguez M; Muñoz-Muela E; Serna-Gallego A; Milanés-Guisado Y; Praena-Fernández JM; Álvarez-Ríos AI; Herrera-Hidalgo L; Domínguez M; Lozano C; Romero-Vazquez G; Roca C; Espinosa N; Gutiérrez-Valencia A; López-Cortés LF
Clin Microbiol Infect; 2022 Aug; 28(8):1151.e9-1151.e16. PubMed ID: 35289296
[TBL] [Abstract][Full Text] [Related]
3. Expression of PD-1 and Tim-3 markers of T-cell exhaustion is associated with CD4 dynamics during the course of untreated and treated HIV infection.
Rallón N; García M; García-Samaniego J; Cabello A; Álvarez B; Restrepo C; Nistal S; Górgolas M; Benito JM
PLoS One; 2018; 13(3):e0193829. PubMed ID: 29518102
[TBL] [Abstract][Full Text] [Related]
4. Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection.
Hoffmann M; Pantazis N; Martin GE; Hickling S; Hurst J; Meyerowitz J; Willberg CB; Robinson N; Brown H; Fisher M; Kinloch S; Babiker A; Weber J; Nwokolo N; Fox J; Fidler S; Phillips R; Frater J;
PLoS Pathog; 2016 Jul; 12(7):e1005661. PubMed ID: 27415828
[TBL] [Abstract][Full Text] [Related]
5. Double Positive CD4
Kochanowicz AM; Osuch S; Berak H; Kumorek A; Caraballo Cortés K
Cells; 2023 May; 12(10):. PubMed ID: 37408280
[TBL] [Abstract][Full Text] [Related]
6. Decrease of T-cells exhaustion markers programmed cell death-1 and T-cell immunoglobulin and mucin domain-containing protein 3 and plasma IL-10 levels after successful treatment of chronic hepatitis C.
Osuch S; Laskus T; Berak H; Perlejewski K; Metzner KJ; Paciorek M; Radkowski M; Caraballo Cortés K
Sci Rep; 2020 Sep; 10(1):16060. PubMed ID: 32994477
[TBL] [Abstract][Full Text] [Related]
7. Phenotype, Polyfunctionality, and Antiviral Activity of
Salido J; Ruiz MJ; Trifone C; Figueroa MI; Caruso MP; Gherardi MM; Sued O; Salomón H; Laufer N; Ghiglione Y; Turk G
Front Immunol; 2018; 9():2443. PubMed ID: 30405632
[TBL] [Abstract][Full Text] [Related]
8. Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study.
Lombardi F; Belmonti S; Borghetti A; Fabbiani M; Marchetti S; Tamburrini E; Cauda R; di Giambenedetto S
J Antimicrob Chemother; 2020 Jun; 75(6):1599-1603. PubMed ID: 32101614
[TBL] [Abstract][Full Text] [Related]
9. Implications of Immune Checkpoint Expression During Aging in HIV-Infected People on Antiretroviral Therapy.
de Armas LR; Pallikkuth S; Rinaldi S; Pahwa R; Pahwa S
AIDS Res Hum Retroviruses; 2019; 35(11-12):1112-1122. PubMed ID: 31578868
[TBL] [Abstract][Full Text] [Related]
10. The effect of protease inhibitor-based dual antiretroviral regimens on CD4/CD8 ratio during the first year of therapy in ART-naïve patients with HIV-infection.
Figueroa MI; Camiro-Zuñiga A; Belaunzaran-Zamudio PF; Sierra Madero J; Andrade Villanueva J; Arribas JR; Lama JR; Cecchini DM; Lopardo G; Crabtree-Ramírez B; Gun A; Patterson P; Fink VI; Sued OG; Cahn P
HIV Med; 2021 Apr; 22(4):254-261. PubMed ID: 33336523
[TBL] [Abstract][Full Text] [Related]
11. CD8
Osuch S; Laskus T; Perlejewski K; Berak H; Bukowska-Ośko I; Pollak A; Zielenkiewicz M; Radkowski M; Caraballo Cortés K
Front Immunol; 2022; 13():832206. PubMed ID: 35386708
[TBL] [Abstract][Full Text] [Related]
12. Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial.
Pulido F; Ribera E; Lagarde M; Pérez-Valero I; Palacios R; Iribarren JA; Payeras A; Domingo P; Sanz J; Cervero M; Curran A; Rodríguez-Gómez FJ; Téllez MJ; Ryan P; Barrufet P; Knobel H; Rivero A; Alejos B; Yllescas M; Arribas JR;
Clin Infect Dis; 2017 Nov; 65(12):2112-2118. PubMed ID: 29020293
[TBL] [Abstract][Full Text] [Related]
13. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW
AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670
[TBL] [Abstract][Full Text] [Related]
14. Expression of programmed cell death protein 1 and T-cell immunoglobulin- and mucin-domain-containing molecule-3 on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus infection and in subjects who spontaneously cleared the virus.
Caraballo Cortés K; Osuch S; Perlejewski K; Pawełczyk A; Kaźmierczak J; Janiak M; Jabłońska J; Nazzal K; Stelmaszczyk-Emmel A; Berak H; Bukowska-Ośko I; Paciorek M; Laskus T; Radkowski M
J Viral Hepat; 2019 Aug; 26(8):942-950. PubMed ID: 30972915
[TBL] [Abstract][Full Text] [Related]
15. HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression.
Vali B; Jones RB; Sakhdari A; Sheth PM; Clayton K; Yue FY; Gyenes G; Wong D; Klein MB; Saeed S; Benko E; Kovacs C; Kaul R; Ostrowski MA
Eur J Immunol; 2010 Sep; 40(9):2493-505. PubMed ID: 20623550
[TBL] [Abstract][Full Text] [Related]
16. Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV.
Martínez-Sanz J; Ron R; Moreno E; Sánchez-Conde M; Muriel A; López Cortés LF; Blanco JR; Pineda JA; Mena Á; Calzado Isbert S; Moreno S; Serrano-Villar S
Front Immunol; 2022; 13():873408. PubMed ID: 35432298
[TBL] [Abstract][Full Text] [Related]
17. Role of thymosin α1 in restoring immune response in immunological nonresponders living with HIV.
Chen C; Wang J; Xun J; Zhang X; Liu L; Song Z; Zhang R; Chen J; Lu H
BMC Infect Dis; 2024 Jan; 24(1):97. PubMed ID: 38233816
[TBL] [Abstract][Full Text] [Related]
18. Reduction of Immune Activation and Partial Recovery of Staphylococcal Enterotoxin B-Induced Cytokine Production After Switching to an Integrase Strand Transfer Inhibitor-Containing Regimen: Results from an Observational Cohort Study.
Merlini E; Cazzaniga FA; Casabianca A; Orlandi C; Magnani M; Ancona G; Tincati C; d'Arminio Monforte A; Marchetti G
Clin Drug Investig; 2019 Dec; 39(12):1239-1249. PubMed ID: 31531832
[TBL] [Abstract][Full Text] [Related]
19. A Cinnamon-Derived Procyanidin Compound Displays Anti-HIV-1 Activity by Blocking Heparan Sulfate- and Co-Receptor- Binding Sites on gp120 and Reverses T Cell Exhaustion via Impeding Tim-3 and PD-1 Upregulation.
Connell BJ; Chang SY; Prakash E; Yousfi R; Mohan V; Posch W; Wilflingseder D; Moog C; Kodama EN; Clayette P; Lortat-Jacob H
PLoS One; 2016; 11(10):e0165386. PubMed ID: 27788205
[TBL] [Abstract][Full Text] [Related]
20. Reversal of the CD8
Li J; Huang HH; Tu B; Zhou MJ; Hu W; Fu YL; Li XY; Yang T; Song JW; Fan X; Jiao YM; Xu RN; Zhang JY; Zhou CB; Yuan JH; Zhen C; Shi M; Wang FS; Zhang C
Front Immunol; 2021; 12():687296. PubMed ID: 34177939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
